On Monday, Heron Therapeutics Inc (NASDAQ: HRTX) opened higher 7.83% from the last session, before settling in for the closing price of $1.66. Price fluctuations for HRTX have ranged from $1.04 to $3.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 0.21% annually for the last half of the decade. Company’s average yearly earnings per share was noted 83.89% at the time writing. With a float of $151.02 million, this company’s outstanding shares have now reached $151.70 million.
In an organization with 126 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 67.55%, operating margin of -17.61%, and the pretax margin is -19.0%.
Heron Therapeutics Inc (HRTX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Heron Therapeutics Inc is 0.71%, while institutional ownership is 80.27%.
Heron Therapeutics Inc (HRTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 83.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 47.50% during the next five years compared to 20.01% growth over the previous five years of trading.
Heron Therapeutics Inc (NASDAQ: HRTX) Trading Performance Indicators
Check out the current performance indicators for Heron Therapeutics Inc (HRTX). In the past quarter, the stock posted a quick ratio of 1.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.18, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.06 in one year’s time.
Technical Analysis of Heron Therapeutics Inc (HRTX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.81 million. That was inferior than the volume of 1.9 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 80.75%. Additionally, its Average True Range was 0.13.
During the past 100 days, Heron Therapeutics Inc’s (HRTX) raw stochastic average was set at 67.57%, which indicates a significant decrease from 89.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.66% in the past 14 days, which was lower than the 97.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5334, while its 200-day Moving Average is $2.3616. However, in the short run, Heron Therapeutics Inc’s stock first resistance to watch stands at $1.8667. Second resistance stands at $1.9433. The third major resistance level sits at $2.0567. If the price goes on to break the first support level at $1.6767, it is likely to go to the next support level at $1.5633. The third support level lies at $1.4867 if the price breaches the second support level.
Heron Therapeutics Inc (NASDAQ: HRTX) Key Stats
There are currently 152,095K shares outstanding in the company with a market cap of 272.25 million. Presently, the company’s annual sales total 127,040 K according to its annual income of -110,560 K. Last quarter, the company’s sales amounted to 32,810 K and its income totaled -4,850 K.
